Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Other research analysts have also issued research reports about the stock. Alliance Global Partners upgraded shares of Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. HC Wainwright lifted their price target on Aptose Biosciences from $2.00 to $6.00 and gave the company a “buy” rating in a research report on Friday, March 28th.

Aptose Biosciences Stock Performance

The stock has a market cap of $3.66 million, a PE ratio of -0.58 and a beta of 1.04. Aptose Biosciences has a 1-year low of $1.35 and a 1-year high of $50.10. The firm’s 50-day simple moving average is $4.41 and its two-hundred day simple moving average is $7.37.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Bleichroeder LP bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned about 4.15% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.